ABCG2 and chronic myelogenous leukemia, BCR-ABL1 positive: Its ability to reverse resistance to 7-ethyl-10-hydroxycamptothecin (SN-38) was investigated using human chronic myelogenous leukaemia cell lines expressing BCRP (K562/BCRP) and non-expressing control cells (K562).